Foghorn Therapeutics
FHTX
79 hedge funds and large institutions have $372M invested in Foghorn Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 6 closing their positions.
318% more call options, than puts
Call options by funds: $92K | Put options by funds: $22K
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
64% more capital invested
Capital invested by funds: $227M → $372M (+$146M)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
10% more funds holding
Funds holding: 72 → 79 (+7)
1% more ownership
Funds ownership: 71.29% → 72.29% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.87M |
| 2 |
DM
Deerfield Management
New York
|
+$3.69M |
| 3 |
BlackRock
New York
|
+$1.92M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.06M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$439K |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$4.14M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.27M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.13M |
| 4 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$1.29M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$429K |
FHTX Hedge Fund Activity: Q3 2024 in Review
79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2024, worth a combined $372M — up 64% from $227M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new FHTX positions and 6 closed out — a net gain of 7 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.87M. The largest seller was Artal Group, exiting entirely with an estimated $4.14M sold.
- 79 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2024, up from 72 in Q2 2024.
- Funds reported $372M of Foghorn Therapeutics stock for Q3 2024, up 64% quarter-over-quarter.
- 13 funds opened new Foghorn Therapeutics positions in Q3 2024 and 6 closed out, a net change of +7 holders.
- The largest Foghorn Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $4.87M added.
- The largest Foghorn Therapeutics seller in Q3 2024 was Artal Group, an estimated $4.14M sold.
Based on aggregated 13F filings for Q3 2024.